Drug intelligence / Profile preview

EMP-CVM

Development stage: Preclinical
Lead developer: Empirico
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Subcutaneous

Overview

EMP-CVM is an investigational small interfering RNA (siRNA) therapeutic being developed by Empirico for the treatment of cardiovascular disease. The drug utilizes a GalNAc (N-acetylgalactosamine) conjugation strategy to enable targeted delivery to the liver, where it leverages the RNA interference (RNAi) pathway to silence a specific, undisclosed mRNA target. Identified through Empirico's genetics-led discovery platform, EMP-CVM is currently in the IND-enabling phase of development, aimed at addressing unmet needs in cardiovascular health by targeting novel pathways identified through human genetics.

Beyond the preview

Go deeper on EMP-CVM.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EMP-CVM.

Explore the full profile